Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin-assisted physiotherapy for refractory motor functional neurological disorder
ACTRN12621000578808Phase 2Completed
- Sponsor
- Austin Health
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of psilocybin in Dissociative neurological symptom disorder (DNSD) (2 arms), sponsored by Austin Health. Primary endpoints: Participant-reported Clinical Global Impression of Severity of FND symptoms, Individualised scale of functional motor disability according to motor symptoms and 3 more. Started May 2024; status: completed.
02
Drugs
psilocybin
03
Conditions
Dissociative neurological symptom disorder (DNSD)
Beyond the preview
Go deeper on ACTRN12621000578808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621000578808.